Borderline Substances Advisory Committee

Department of Health and Social Care written question – answered on 29th November 2021.

Alert me about debates like this

Photo of Alex Norris Alex Norris Shadow Minister (Health and Social Care)

To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the Advisory Committee on Borderline Substances to facilitate product innovation and patient choice.

Photo of Edward Argar Edward Argar Minister of State (Department of Health and Social Care)

The Advisory Committee on Borderline Substances (ACBS) application process has a specified route for innovative products seeking listing in Part XV of the Drug Tariff. This route is for new formulations where there is robust evidence of advantages in terms of nutritional composition and tolerance and acceptability for patients. Products approved and recommended by the ACBS are listed in Part XV of the Drug Tariff. The ACBS list in the Drug Tariff offers some patient choice where the relevant products are available and meet the quality criteria.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.